Incurin

Incurin

Incurin Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Human Warnings

Not for human use. Keep out of the reach of children. Women who are of child-bearing age or those who are breastfeeding should use caution when administering INCURIN™ Tablets. Wash your hands with soap and water after administration to avoid exposure to the drug. Consult a physician in case of accidental ingestion by humans.

Animal Warnings

Some estrogens have been associated with bone marrow changes and an increased risk of mammary tumors. However, target animal safety study results and foreign post-market pharmacovigilance data for INCURIN™ Tablets have shown that estriol-treated dogs are at low risk for developing these conditions.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

INCURIN™ Tablets are indicated for the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs.

History

There is currently no drug history available for this drug.

Other Information

INCURIN™ (estriol) Tablets contain 1 mg of estriol per tablet.

Chemical Structure

USP Chemical Name: Estra-1,3,5(10)-triene-3,16,17-triol, (16α,17β)-.

USP Molecular Weight: 288.38

USP Solubility: Soluble in acetone, in chloroform, in dioxane, in ether, and in vegetable oils; sparingly soluble in alcohol; insoluble in water.

Incurin Manufacturers


  • Merck Sharp & Dohme Corp.
    Incurin (Estriol) Tablet [Merck Sharp & Dohme Corp.]

Login To Your Free Account